Oscar M. Rueda

Oscar M. Rueda

Auto-generated profile, based on publicly available information

Oscar M. Rueda

University of Cambridge

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 December 2021 in Nature
Verified
Journal Article
Open access
PDF file
SSStephen-John Sammut
Stephen-John Sammut
MCMireia Crispin-Ortuzar
Mireia Crispin-Ortuzar
SCSuet-Feung Chin
Suet-Feung Chin
EPElena Provenzano
Elena Provenzano
HBHelen A. Bardwell
Helen A. Bardwell
CCCarlos Caldas
Carlos Caldas
Breast cancers are complex ecosystems of malignant cells and the tumour microenvironment1. The composition of these tumour ecosystems and interactions within them contribute to responses to cytotoxic therapy2. Efforts to build response predictors have not incorporated this knowledge. We collected clinical, digital pathology, genomic and transcriptomic profiles of pre-treatment biopsies of breast tumours from 168 patients treated with chemotherapy with or without HER2 (encoded byERBB2)-targeted therapy before surgery. Pathology end points (complete response or residual disease) at surgery3were then correlated with multi-omic features in these diagnostic biopsies. Here we show that response to treatment is modulated by the pre-treated tumour ecosystem, and its multi-omics landscape can be integrated in predictive models using machine learning. The degree of residual disease following therapy is monotonically associated with pre-therapy features, including tumour mutational and copy number landscapes, tumour proliferation, immune infiltration and T cell dysfunction and exclusion. Combining these features into a multi-omic machine learning model predicted a pathological complete response in an external validation cohort (75 patients) with an area under the curve of 0.87. In conclusion, response to therapy is determined by the baseline characteristics of the totality of the tumour ecosystem captured through data integration and machine learning. This approach could be used to develop predictors for other cancers.

14 February 2020 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
HAH. Raza Ali
H. Raza Ali
HJHartland W. Jackson
Hartland W. Jackson
VZVito R. T. Zanotelli
Vito R. T. Zanotelli
EDEsther Danenberg
Esther Danenberg
JFJana R. Fischer
Jana R. Fischer
BBBernd Bodenmiller
Bernd Bodenmiller

18 April 2022 in Nature Genetics
Verified
Journal Article
Open access
PDF file
EDEsther Danenberg
Esther Danenberg
HBHelen Bardwell
Helen Bardwell
VZVito R. T. Zanotelli
Vito R. T. Zanotelli
EPElena Provenzano
Elena Provenzano
SCSuet-Feung Chin
Suet-Feung Chin
HAH. Raza Ali
H. Raza Ali
The functions of the tumor microenvironment (TME) are orchestrated by precise spatial organization of specialized cells, yet little is known about the multicellular structures that form within the TME. Here we systematically mapped TME structures in situ using imaging mass cytometry and multitiered spatial analysis of 693 breast tumors linked to genomic and clinical data. We identified ten recurrent TME structures that varied by vascular content, stromal quiescence versus activation, and leukocyte composition. These TME structures had distinct enrichment patterns among breast cancer subtypes, and some were associated with genomic profiles indicative of immune escape. Regulatory and dysfunctional T cells co-occurred in large ‘suppressed expansion’ structures. These structures were characterized by high cellular diversity, proliferating cells and enrichment forBRCA1andCASP8mutations and predicted poor outcome in estrogen-receptor-positive disease. The multicellular structures revealed here link conserved spatial organization to local TME function and could improve patient stratification.

3 August 2020 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
RHRobert Hänsel-Hertsch
Robert Hänsel-Hertsch
ASAngela Simeone
Angela Simeone
ASAbigail Shea
Abigail Shea
WHWinnie W. I. Hui
Winnie W. I. Hui
KZKatherine G. Zyner
Katherine G. Zyner
SBShankar Balasubramanian
Shankar Balasubramanian

22 December 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
JPJia-Wern Pan
Jia-Wern Pan
MZMuhammad Mamduh Ahmad Zabidi
Muhammad Mamduh Ahmad Zabidi
PNPei-Sze Ng
Pei-Sze Ng
MMMei-Yee Meng
Mei-Yee Meng
SHSiti Norhidayu Hasan
Siti Norhidayu Hasan
STSoo Hwang Teo
Soo Hwang Teo
Molecular profiling of breast cancer has enabled the development of more robust molecular prognostic signatures and therapeutic options for breast cancer patients. However, non-Caucasian populations remain understudied. Here, we present the mutational, transcriptional, and copy number profiles of 560 Malaysian breast tumours and a comparative analysis of breast cancers arising in Asian and Caucasian women. Compared to breast tumours in Caucasian women, we show an increased prevalence of HER2-enriched molecular subtypes and higher prevalence of TP53 somatic mutations in ER+ Asian breast tumours. We also observe elevated immune scores in Asian breast tumours, suggesting potential clinical response to immune checkpoint inhibitors. Whilst HER2-subtype and enriched immune score are associated with improved survival, presence of TP53 somatic mutations is associated with poorer survival in ER+ tumours. Taken together, these population differences unveil opportunities to improve the understanding of this disease and lay the foundation for precision medicine in different populations.

13 September 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
RBRajbir Nath Batra
Rajbir Nath Batra
ALAviezer Lifshitz
Aviezer Lifshitz
AVAna Tufegdzic Vidakovic
Ana Tufegdzic Vidakovic
SCSuet-Feung Chin
Suet-Feung Chin
ASAnkita Sati-Batra
Ankita Sati-Batra
CCCarlos Caldas
Carlos Caldas
DNA methylation is aberrant in cancer, but the dynamics, regulatory role and clinical implications of such epigenetic changes are still poorly understood. Here, reduced representation bisulfite sequencing (RRBS) profiles of 1538 breast tumors and 244 normal breast tissues from the METABRIC cohort are reported, facilitating detailed analysis of DNA methylation within a rich context of genomic, transcriptional, and clinical data. Tumor methylation from immune and stromal signatures are deconvoluted leading to the discovery of a tumor replication-linked clock with genome-wide methylation loss in non-CpG island sites. Unexpectedly, methylation in most tumor CpG islands follows two replication-independent processes of gain (MG) or loss (ML) that we term epigenomic instability. Epigenomic instability is correlated with tumor grade and stage, TP53 mutations and poorer prognosis. After controlling for these global trans-acting trends, as well as for X-linked dosage compensation effects, cis-specific methylation and expression correlations are uncovered at hundreds of promoters and over a thousand distal elements. Some of these targeted known tumor suppressors and oncogenes. In conclusion, this study demonstrates that global epigenetic instability can erode cancer methylomes and expose them to localized methylation aberrations in-cis resulting in transcriptional changes seen in tumors.